Table 2 Univariate survival analyses for the patients with SSC of ovary in the SEER database (2004–2016, N = 180)
Overall survival | Cause-specific survival | |||||
|---|---|---|---|---|---|---|
Variables | HR | 95%CI | P-value | HR | 95%CI | P-value |
Age | ||||||
≤67 | 1 | 1 | ||||
> 67 | 2.24 | 1.48–3.38 | < 0.001 | 1.91 | 1.16–3.14 | 0.011 |
Race | ||||||
White | 1 | 1 | ||||
Black | 1.08 | 0.60–1.94 | 0.798 | 0.85 | 0.39–1.86 | 0.677 |
Others | 0.86 | 0.48–1.62 | 0.638 | 0.96 | 0.47–1.94 | 0.901 |
Tumor size (mm) | ||||||
< 50 | 1 | 1 | ||||
50–150 | 1.99 | 1.05–3.75 | 0.034 | 2.23 | 0.99–5.07 | 0.054 |
> 150 | 1.75 | 0.82–3.74 | 0.150 | 2.12 | 0.84–5.32 | 0.110 |
Laterality | ||||||
Unilateral | 1 | 1 | ||||
Bilateral | 2.83 | 1.37–5.85 | 0.005 | 3.33 | 1.44–7.70 | 0.005 |
Serum CA125 | ||||||
Negative | 1 | 1 | ||||
Positive | 1.42 | 0.78–2.57 | 0.248 | 1.82 | 0.86–3.83 | 0.116 |
FIGO stage | ||||||
I | 1 | 1 | ||||
II | 2.62 | 1.43–4.79 | 0.002 | 4.06 | 1.93–8.54 | < 0.001 |
III | 2.99 | 1.66–5.36 | < 0.001 | 3.30 | 1.54–7.06 | 0.002 |
IV | 9.56 | 5.27–17.36 | < 0.001 | 16.52 | 7.86–34.72 | < 0.001 |
Grade | ||||||
G1/G2 | 1 | |||||
G3/G4 | 1.23 | 0.78–1.92 | 0.371 | 1.18 | 0.70–2.02 | 0.533 |
SEER stage | ||||||
Localized | 1 | 1 | ||||
Regional | 2.62 | 1.37–5.03 | 0.004 | 4.27 | 1.77–10.33 | 0.001 |
Distant | 6.40 | 3.38–12.1 | < 0.001 | 9.70 | 4.06–23.15 | < 0.001 |
Lymphadenectomy | ||||||
Yes | 1 | 1 | ||||
No | 1.67 | 1.11–2.50 | 0.014 | 1.70 | 1.04–2.78 | 0.034 |
Radiotherapy | ||||||
Yes | 1 | 1 | ||||
No | 0.76 | 0.47–1.22 | 0.254 | 0.57 | 0.33–0.98 | 0.041 |
Chemotherapy | ||||||
Yes | 1 | 1 | ||||
No | 1.01 | 0.68–1.49 | 0.964 | 1.21 | 0.75–1.94 | 0.437 |
Surgery | ||||||
Yes | 1 | |||||
No | 2.80 | 1.49–5.25 | 0.001 | 3.14 | 1.36–7.27 | 0.007 |